Just diagnosed with DCIS and need guidance on treatment?
The information provided by DCISionRT can help you and your physician determine how much, if at all, radiation will decrease your personal likelihood of DCIS recurrence or invasive breast cancer. Before you make a decision, Know Your Risk™.
Talk to Nurse Dede today
for more information to help you decide if you need radiation after surgery.
DCISionRT can help you and your physician determine how much, if at all, radiation will decrease your personal likelihood of DCIS recurrence or invasive breast cancer.
The Most Accurate Test for DCIS
The DCISionRT test quantifies the risk of your DCIS coming back (recurring) as well as predicting whether radiation therapy will benefit you.
Your Biology
DCISionRT looks at the biology of your DCIS using a comprehensive assessment of the key pathways implicated in progression of breast cancer.
Your DCISionScore™
Intelligent risk algorithms built with AI trained with thousands of patients calculate your individualized DCISionScore. Your DCISionScore gives your personal prognosis after treatment with surgery alone or surgery and RT.
Your Decision
DCISionRT helps you and your doctor formulate a more precise treatment plan to balance treatment benefit with the risk of side effects by assessing your underlying DCIS biology.
Case Studies
The DCISionRT® test indicates your individual risk of recurrence and expected benefit from radiation therapy.
Example 1
Age: 54 years | DCIS Grade: High (Grade 3) | DCIS size: 12mm
Before DCISionRT
Risk Assessment
Traditional Clinpath Features
TREATMENT PLAN:
Surgery with radiation therapy
TREATMENT RATIONALE:
Radiation therapy after breast conserving surgery is recommended based on presence of high grade (grade 3) DCIS.
After DCISionRT
Risk Assessment
TREATMENT PLAN:
Breast conserving surgery
TREATMENT RATIONALE:
Because the patient has a Low DCISionRT score, the Physician and patient decide to defer radiation therapy and elect breast conserving surgery in order to preserve the option for radiation therapy should the patient have a recurrence in the future.
Example 2
Age: 65 years | DCIS Grade: Low (Grade 1) | DCIS size: 6mm
Before DCISionRT
Risk Assessment
Traditional Clinpath Features
TREATMENT PLAN:
Breast conserving surgery
TREATMENT RATIONALE:
Traditional risk assessment using clinicopathologic features indicates patient could be considered “low risk” and therefore, the patient and physician elect to forego radiation therapy.
After DCISionRT
Risk Assessment
TREATMENT PLAN:
Surgery with radiation therapy
TREATMENT RATIONALE:
New information from DCISionRT indicates the patient is at Elevated Risk if treated with surgery alone. The patient and physician decide to use radiation therapy-–despite traditionally low risk clinicopathalogic features—due to the large risk reduction from radiation therapy.
FAQs
DCISionRT is a risk assessment test for patients with ductal carcinoma in situ (DCIS). The test was developed by PreludeDx and built on research that began with funding from the National Cancer Institute to better understand the biology of DCIS. DCISionRT assesses a patient’s individual biology along with other risk factors to provide a personalized assessment that predicts the risk of your DCIS coming back (recurring) over the next 10 years. The test calculates a personalized recurrence score and identifies your risk as low or elevated. DCISionRT provides information that may help you and your physician make a more informed treatment decision.
PreludeDx is leading the way with unsurpassed turnaround time and provides results in as little as 3-5 days from receiving your specimen. We understand the anxiety associated with uncertainty and strive to get you results quickly so that you and your doctor can make an informed decision.
PreludeDx currently accepts all insurance plans. As with all healthcare, your insurance may include a deductible, co-insurance or co-pay amount depending on your individual plan. PreludeDx is sensitive to all patient needs and offers a variety of financial assistance programs. Contact our Patient Care Team, at 888.211.3247 for more information.
DCISionRT is the latest innovation for DCIS patients. Physicians across the country, including the top US cancer centers use DCISionRT in their treatment planning. If you have questions about discussing this new test with your doctor, please contact our Customer Care team at 888.211.3247.
If you are interested in speaking with a patient advocate, please contact our Customer Care Team at 888.211.3247.